Rapport Therapeutics, Inc. (RAPP) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Rapport Therapeutics is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator being developed for focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS), and bipolar mania. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $0 | $0 | $20,000 | $0 |
| Total Operating Expenses | $60,806 | $29,496 | $105,021 | $56,604 |
| - Research & Development | $51,414 | $22,680 | $84,130 | $42,252 |
| - Selling, General & Admin | $9,392 | $6,816 | $20,891 | $14,352 |
| Net Loss | $(56,615) | $(26,732) | $(76,472) | $(50,795) |
| Net Loss Per Share (Basic/Diluted) | $(1.19) | $(0.75) | $(1.61) | $(1.44) |
| Cash, Cash Equivalents & Short-Term Investments | $436.1 million (as of June 30, 2026) | |||
| Accumulated Deficit | $311.7 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $20.0 million in collaboration revenue during the six months ended June 30, 2026, derived from a non-refundable upfront payment received from Tenacia Biotechnology (Hong Kong) Co., Ltd. for the exclusive license to develop and commercialize RAP-219 in mainland China, Hong Kong, Macau, and Taiwan. No revenue was recognized in the comparable prior period.
- Expense Growth: Total operating expenses increased by approximately 107% year-over-year for the six-month period (from $56.6 million to $105.0 million). This increase was driven primarily by a $32.3 million rise in RAP-219 program costs, attributed to the initiation of Phase 3 trials for FOS, an open-label long-term safety trial, and a Phase 2 trial for bipolar mania.
- Interest Income: Interest income increased to $8.5 million for the six months ended June 30, 2026, compared to $5.8 million in the prior year, due to higher cash balances following the September 2025 public offering.
Guidance, Outlook, and Management Commentary
- Clinical Progress:
- FOS: Phase 3 trials for drug-resistant focal onset seizures were initiated in Q2 2026 following positive Phase 2a topline results announced in September 2025. Follow-up data from the Phase 2a trial indicated sustained efficacy during an 8-week follow-up period.
- Bipolar Mania: The Phase 2 proof-of-concept trial is progressing, with topline results expected in October 2026. The company has modified the statistical analysis plan to potentially support confirmatory evidence.
- DPNP: The FDA removed a clinical hold on the diabetic peripheral neuropathic pain (DPNP) IND in December 2025; however, the company is deferring further investment in this program to prioritize the RAP-641 program.
- Liquidity: As of June 30, 2026, the company held $436.1 million in cash, cash equivalents, and short-term investments. Management believes these resources are sufficient to fund operations and capital expenditures into the second half of 2029.
- Capital Resources: The company completed a $269.4 million underwritten public offering in September 2025. It maintains an At-The-Market (ATM) program with up to $150.0 million available for sale, though no shares have been sold under this program as of June 30, 2026.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the need for additional capital if burn rates increase, dependence on third-party manufacturers (including potential impacts of the BIOSECURE Act on Chinese suppliers), and reliance on the Tenacia collaboration for the Greater China market.
Investor Verification Checklist
- Revenue Sustainability: Verify the terms of the Tenacia License Agreement to understand the timing and probability of future milestone payments and royalties beyond the initial $20 million upfront fee.
- Cash Burn Rate: Monitor the quarterly increase in R&D expenses, specifically the costs associated with the newly initiated Phase 3 trials, to assess if the current cash runway (projected to late 2029) remains accurate.
- Manufacturing Supply Chain: Review disclosures regarding third-party manufacturers, particularly those located in China, to evaluate exposure to the BIOSECURE Act and potential supply chain disruptions.
- Clinical Trial Enrollment: Track patient enrollment rates for the Phase 3 FOS trials and the Phase 2 bipolar mania trial, as delays could significantly impact the timeline for regulatory approval.
- Regulatory Status: Confirm the status of the DPNP program and any future regulatory interactions regarding the long-acting injectable (LAI) formulation of RAP-219.